Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, Mooney L, Hughes A, Jarvis L, Staniszewska A, Crafter C, Sidders B, Hardaker E, Hudson K, Barry ST. Carnevalli LS, et al. Among authors: hardaker e. J Immunother Cancer. 2018 Dec 27;6(1):158. doi: 10.1186/s40425-018-0457-0. J Immunother Cancer. 2018. PMID: 30587236 Free PMC article.
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL. Taylor MA, et al. Among authors: hardaker el. J Immunother Cancer. 2019 Nov 28;7(1):328. doi: 10.1186/s40425-019-0794-7. J Immunother Cancer. 2019. PMID: 31779705 Free PMC article.
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
McCoull W, Boyd S, Brown MR, Coen M, Collingwood O, Davies NL, Doherty A, Fairley G, Goldberg K, Hardaker E, He G, Hennessy EJ, Hopcroft P, Hodgson G, Jackson A, Jiang X, Karmokar A, Lainé AL, Lindsay N, Mao Y, Markandu R, McMurray L, McLean N, Mooney L, Musgrove H, Nissink JWM, Pflug A, Reddy VP, Rawlins PB, Rivers E, Schimpl M, Smith GF, Tentarelli S, Travers J, Troup RI, Walton J, Wang C, Wilkinson S, Williamson B, Winter-Holt J, Yang D, Zheng Y, Zhu Q, Smith PD. McCoull W, et al. Among authors: hardaker e. J Med Chem. 2021 Sep 23;64(18):13524-13539. doi: 10.1021/acs.jmedchem.1c00920. Epub 2021 Sep 3. J Med Chem. 2021. PMID: 34478292
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.
Lundin A, Porritt MJ, Jaiswal H, Seeliger F, Johansson C, Bidar AW, Badertscher L, Wimberger S, Davies EJ, Hardaker E, Martins CP, James E, Admyre T, Taheri-Ghahfarokhi A, Bradley J, Schantz A, Alaeimahabadi B, Clausen M, Xu X, Mayr LM, Nitsch R, Bohlooly-Y M, Barry ST, Maresca M. Lundin A, et al. Among authors: hardaker e. Nat Commun. 2020 Sep 29;11(1):4903. doi: 10.1038/s41467-020-18548-9. Nat Commun. 2020. PMID: 32994412 Free PMC article.
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Nissink JWM, Bazzaz S, Blackett C, Clark MA, Collingwood O, Disch JS, Gikunju D, Goldberg K, Guilinger JP, Hardaker E, Hennessy EJ, Jetson R, Keefe AD, McCoull W, McMurray L, Olszewski A, Overman R, Pflug A, Preston M, Rawlins PB, Rivers E, Schimpl M, Smith P, Truman C, Underwood E, Warwicker J, Winter-Holt J, Woodcock S, Zhang Y. Nissink JWM, et al. Among authors: hardaker e. J Med Chem. 2021 Mar 25;64(6):3165-3184. doi: 10.1021/acs.jmedchem.0c01904. Epub 2021 Mar 8. J Med Chem. 2021. PMID: 33683117
Development of autotaxin inhibitors: A series of tetrazole cinnamides.
Thomson CG, Le Grand D, Dowling M, Beattie D, Elphick L, Faller M, Freeman M, Hardaker E, Head V, Hemmig R, Hill J, Lister A, Pascoe D, Rieffel S, Shrestha B, Steward O, Zink F. Thomson CG, et al. Among authors: hardaker e. Bioorg Med Chem Lett. 2021 Jan 1;31:127663. doi: 10.1016/j.bmcl.2020.127663. Epub 2020 Nov 4. Bioorg Med Chem Lett. 2021. PMID: 33160025
Development of autotaxin inhibitors: A series of zinc binding triazoles.
Thomson CG, Le Grand D, Dowling M, Brocklehurst CE, Chinn C, Elphick L, Faller M, Freeman M, Furminger V, Gasser C, Hamadi A, Hardaker E, Head V, Hill JC, Janus DI, Pearce D, Poulaud AS, Stanley E, Sviridenko L. Thomson CG, et al. Among authors: hardaker e. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2279-2284. doi: 10.1016/j.bmcl.2018.05.030. Epub 2018 May 21. Bioorg Med Chem Lett. 2018. PMID: 29798825
28 results